Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
Medtronic
McKesson
Boehringer Ingelheim

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR COTELLIC


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cotellic

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01656642 ↗ A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma Completed Genentech, Inc. Phase 1 2012-08-13 This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in participants with BRAFV600-mutation positive metastatic melanoma. Enrolled participants may continue treatment until they are no longer experiencing clinical benefit as assessed by the investigator and in alignment with the protocol.
NCT01928394 ↗ A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting Bristol-Myers Squibb Phase 1/Phase 2 2013-10-24 To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.
NCT02060188 ↗ An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Active, not recruiting Bristol-Myers Squibb Phase 2 2014-03-12 The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in patients with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.
NCT02091141 ↗ My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Active, not recruiting Genentech, Inc. Phase 2 2014-04-14 This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.
NCT02303951 ↗ Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC Terminated University Hospital Tuebingen Phase 2 2015-01-22 Evaluation of the efficacy, safety and biologic effects of neo-adjuvant treatment with vemurafenib + cobimetinib + atezolizumab in patients with limited metastasis of melanoma in stage IIIC/IV melanoma.
NCT03101254 ↗ LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma Active, not recruiting Eli Lilly and Company Phase 1/Phase 2 2017-06-06 This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are: - LY3022855 - Vemurafenib - Cobimetinib
NCT03101254 ↗ LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma Active, not recruiting Dana-Farber Cancer Institute Phase 1/Phase 2 2017-06-06 This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are: - LY3022855 - Vemurafenib - Cobimetinib
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cotellic

Condition Name

Condition Name for Cotellic
Intervention Trials
Malignant Melanoma 3
Stage II Pancreatic Cancer AJCC v8 3
Stage IIA Pancreatic Cancer AJCC v8 3
Stage IIB Pancreatic Cancer AJCC v8 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cotellic
Intervention Trials
Melanoma 11
Neoplasms 9
Carcinoma 7
Adenocarcinoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cotellic

Trials by Country

Trials by Country for Cotellic
Location Trials
United States 143
Italy 12
Spain 10
Australia 10
Brazil 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cotellic
Location Trials
Texas 14
Tennessee 10
Oregon 8
Massachusetts 8
New York 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cotellic

Clinical Trial Phase

Clinical Trial Phase for Cotellic
Clinical Trial Phase Trials
Phase 3 1
Phase 2 19
Phase 1/Phase 2 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cotellic
Clinical Trial Phase Trials
Recruiting 17
Active, not recruiting 9
Completed 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cotellic

Sponsor Name

Sponsor Name for Cotellic
Sponsor Trials
Genentech, Inc. 11
National Cancer Institute (NCI) 8
Hoffmann-La Roche 5
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cotellic
Sponsor Trials
Other 28
Industry 24
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.